

# Non-Hodgkin Lymphoma Market - 2023

<https://marketpublishers.com/r/NCEB009AE52FEN.html>

Date: November 2025

Pages: 217

Price: US\$ 2,999.00 (Single User License)

ID: NCEB009AE52FEN

## Abstracts

The Non-Hodgkin Lymphoma Market was valued at USD 7.3 billion in 2023 and is anticipated to reach by , at a CAGR of 0.082 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Non-Hodgkin Lymphoma Market.

This report delivers a comprehensive overview of the Non-Hodgkin Lymphoma Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non-Hodgkin Lymphoma Market. The Non-Hodgkin Lymphoma Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–.

Non-Hodgkin Lymphoma Market Scope:

By Disease Type

B-cell Lymphomas

T-cell Lymphoma

## By Drug Class

Monoclonal Antibodies

Antibody-Drug Conjugates

BTK/BCL-2 Kinase Inhibitors

PI3 Kinase Inhibitors

Protease Inhibitors

PD1 Inhibitors

Immunomodulatory Drugs

Chemotherapy Agents

CAR T-Cell Therapy

## By Route of Administration

Oral

Parenteral

Others

## By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

## Key Players

AbbVie, Inc. (Pharmacyclics LLC)

AstraZeneca plc

Bayer AG

Bristol-Myers Squibb Company (Celgene Corp.)

Gilead Sciences, Inc. (Kite Pharma)

Johnson & Johnson (Janssen Biotech, Inc.)

Merck & Co., Inc.

Novartis AG

Roche Holding AG (F. Hoffmann-La Roche AG)

Seagen, Inc. (Seattle Genetics, Inc.)

Takeda Pharmaceutical Co., Ltd.

Teva Pharmaceutical Industries Ltd.(LIST NOT EXHAUSTIVE)

## Major Highlights

This report delivers a comprehensive overview of the Non-Hodgkin Lymphoma Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non-Hodgkin Lymphoma Market. The Non-Hodgkin Lymphoma Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for

the overall market and its sub-segments, by company, by Type, by Application, and by region.

#### Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

#### Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

#### Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client,

gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

## Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

## Contents

### **1. METHODOLOGY AND SCOPE**

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

### **2. DEFINITION AND OVERVIEW**

### **3. EXECUTIVE SUMMARY**

- 3.1. Snippet by Disease Type
- 3.2. Snippet by Drug Class
- 3.3. Snippet by Route of Administration
- 3.4. Snippet by Distribution Channel
- 3.5. Snippet by Region

### **4. DYNAMICS**

- 4.1. Impacting Factors
  - 4.1.1. Drivers
    - 4.1.1.1. The Growing Regulatory Approvals for Non-Hodgkin Lymphoma
    - 4.1.1.2. The Increasing Clinical Trials for Non-Hodgkin Lymphoma Drugs
  - 4.1.2. Restraints
    - 4.1.2.1. Lack of Specific Targeted Therapies for Treating Non-Hodgkin Lymphoma
  - 4.1.3. Opportunity
    - 4.1.3.1. Exploring Combination Therapies for Enhanced Non-Hodgkin Lymphoma Treatment
  - 4.1.4. Impact Analysis

### **5. INDUSTRY ANALYSIS**

- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Unmet Needs
- 5.4. Regulatory Analysis

### **6. COVID-19 ANALYSIS**

- 6.1. Analysis of COVID-19
  - 6.1.1. Scenario Before COVID-19
  - 6.1.2. Scenario During COVID-19
  - 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers' Strategic Initiatives
- 6.6. Conclusion

## **7. RUSSIA-UKRAINE WAR ANALYSIS**

## **8. BY DISEASE TYPE**

- 8.1. Introduction
  - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  - 8.1.2. Market Attractiveness Index, By Disease Type
- 8.2. B-cell Lymphomas\*
  - 8.2.1. Introduction
  - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. T-cell Lymphoma

## **9. BY DRUG CLASS**

- 9.1. Introduction
  - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  - 9.1.2. Market Attractiveness Index, By Drug Class
- 9.2. Monoclonal Antibodies\*
  - 9.2.1. Introduction
  - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Antibody-Drug Conjugates
- 9.4. BTK/BCL-2 Kinase Inhibitors
- 9.5. PI3 Kinase Inhibitors
- 9.6. Protease Inhibitors
- 9.7. PD1 Inhibitors
- 9.8. Immunomodulatory Drugs
- 9.9. Chemotherapy Agents
- 9.10. CAR T-Cell Therapy

## **10. BY ROUTE OF ADMINISTRATION**

### 10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

10.1.2. Market Attractiveness Index, By Route of Administration

### 10.2. Oral\*

10.2.1. Introduction

10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

### 10.3. Parenteral

### 10.4. Others

## **11. BY DISTRIBUTION CHANNEL**

11.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11.2. Market Attractiveness Index, By Distribution Channel

### 11.1. Hospital Pharmacies\*

11.1.1. Introduction

11.1.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

### 11.2. Retail Pharmacies

### 11.3. Online Pharmacies

## **12. BY REGION**

### 12.1. Introduction

12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

12.1.2. Market Attractiveness Index, By Region

### 12.2. North America

12.2.1. Introduction

12.2.2. Key Region-Specific Dynamics

12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

12.2.7.1. The U.S.

12.2.7.2. Canada

12.2.7.3. Mexico

## 12.3. Europe

### 12.3.1. Introduction

### 12.3.2. Key Region-Specific Dynamics

### 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

### 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

### 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of

#### Administration

### 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

### 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

#### 12.3.7.1. Germany

#### 12.3.7.2. The U.K.

#### 12.3.7.3. France

#### 12.3.7.4. Italy

#### 12.3.7.5. Spain

#### 12.3.7.6. Rest of Europe

## 12.4. South America

### 12.4.1. Introduction

### 12.4.2. Key Region-Specific Dynamics

### 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

### 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

### 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of

#### Administration

### 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

### 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

#### 12.4.7.1. Brazil

#### 12.4.7.2. Argentina

#### 12.4.7.3. Rest of South America

## 12.5. Asia Pacific

### 12.5.1. Introduction

### 12.5.2. Key Region-Specific Dynamics

### 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

### 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

### 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of

#### Administration

### 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

### 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

#### 12.5.7.1. China

#### 12.5.7.2. India

#### 12.5.7.3. Japan

12.5.7.4. Australia

12.5.7.5. Rest of Asia Pacific

12.6. Middle East and Africa

12.6.1. Introduction

12.6.2. Key Region-Specific Dynamics

12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

## **13. COMPETITIVE LANDSCAPE**

13.1. Competitive Scenario

13.2. Product Benchmarking

13.3. Company Share Analysis

13.4. Key Developments and Strategies

## **14. COMPANY PROFILES**

14.1. AbbVie, Inc. (Pharmacyclics LLC) \*

14.1.1. Company Overview

14.1.2. Product Portfolio and Description

14.1.3. Financial Overview

14.1.4. Key Developments

14.2. AstraZeneca plc

14.3. Bayer AG

14.4. Bristol-Myers Squibb Company (Celgene Corp.)

14.5. Gilead Sciences, Inc. (Kite Pharma)

14.6. Johnson & Johnson (Janssen Biotech, Inc.)

14.7. Merck & Co., Inc.

14.8. Novartis AG

14.9. Roche Holding AG (F. Hoffmann-La Roche AG)

14.10. Seagen, Inc. (Seattle Genetics, Inc.)

14.11. Takeda Pharmaceutical Co., Ltd.

14.12. Teva Pharmaceutical Industries Ltd. (\*LIST NOT EXHAUSTIVE)

## **15. APPENDIX**

15.1. About Us and Services

15.2. Contact Us

## I would like to order

Product name: Non-Hodgkin Lymphoma Market - 2023

Product link: <https://marketpublishers.com/r/NCEB009AE52FEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NCEB009AE52FEN.html>